KRN5500 is a non-narcotic, non-opioid, analgesic agent produced by Streptomyces alanosinicus.
According to the Phase II, double-blind, placebo-controlled, randomized, dose escalation study, KRN5500 showed significant improvement in the relief of neuropathic pain as compared to placebo.
About 50% of KRN5500 patients achieved greater than or equal to 30% improvement in pain intensity compared to 14% of placebo patients.
The data has been published in the Journal of Pain and Symptom Management.